EP2706057A1 — Bis(imidazolyl)compounds and radionuclide complexes
Assigned to Molecular Insight Pharmaceuticals Inc · Expires 2014-03-12 · 12y expired
What this patent protects
Complexes of heterocyclic radionuclides are prepared based upon ligands having substituted imidazolyl groups. The ligands are bifunctional, having amino acid residues that may act as a linker to a bioactive molecule, and a tridentate chelator that may complex the radionuclide. Th…
USPTO Abstract
Complexes of heterocyclic radionuclides are prepared based upon ligands having substituted imidazolyl groups. The ligands are bifunctional, having amino acid residues that may act as a linker to a bioactive molecule, and a tridentate chelator that may complex the radionuclide. The bioactive molecule may be a peptide or somatostatin.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.